GO:0014824 artery smooth muscle contraction: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0014824 describes the biological process by which arterial smooth muscle generates force through actin-myosin ATP hydrolysis, altering vessel geometry.
• Arterial smooth muscle contraction is often rhythmic or tonic, and its dynamics depend on wall structure and smooth muscle orientation.
• Protein phosphorylation, particularly of myosin light chain, is a central regulatory step during contraction-relaxation cycles in arteries.
• Pharmacological agents such as cyclosporine, simvastatin, and Rac/cytohesin/kinase inhibitors can selectively modulate arterial smooth muscle contraction.
• Contraction of arterial smooth muscle influences mechanical properties such as critical buckling pressure, linking cellular force generation to vessel stability.
• Studying GO:0014824 requires integrating contractility assays, phosphorylation analysis, and genetic models to dissect gene function in vascular tone.
Description
Artery smooth muscle contraction (GO:0014824) is a fundamental biological process in which smooth muscle tissue within arteries generates force, leading to changes in muscle geometry and vessel caliber. This process is driven by the chemo-mechanical energy conversion carried out by the actin/myosin complex, which hydrolyzes ATP to produce force. Because arteries carry blood away from the heart, the contractile state of their smooth muscle directly influences vascular resistance, blood pressure, and organ perfusion. Researchers study this process to understand vascular physiology, the pathogenesis of hypertension and vasospasm, and the mechanisms of vasoactive drugs. The rhythmicity and orientation of smooth muscle cells further modulate how force translates into vessel narrowing or stiffening. Consequently, GO:0014824 serves as a key ontology term for annotating genes and pathways involved in arterial contractility.
artery smooth muscle contraction At A Glance
| GO ID | GO:0014824 |
|---|---|
| GO term | artery smooth muscle contraction |
| Ontology | biological_process |
| Synonym | none |
| Major function | Force generation within arterial smooth muscle tissue via actin/myosin ATP hydrolysis, leading to changes in muscle geometry and vessel caliber. |
| Related anatomy | Artery (blood vessel carrying blood away from the heart). |
| Key molecular players | Actin, myosin, myosin light chain kinase, myosin light chain phosphatase, RhoA/ROCK, calcium channels. |
| Physiological outcomes | Regulation of vascular tone, blood pressure, and organ blood flow; rhythmic contractions in some arteries. |
| Pharmacological relevance | Target of vasoactive drugs such as cyclosporine, simvastatin, and Rac/cytohesin/kinase inhibitors. |
What Is GO:0014824?
GO:0014824, artery smooth muscle contraction, is defined as a process in which force is generated within smooth muscle tissue of an artery, resulting in a change in muscle geometry. The force generation involves a chemo-mechanical energy conversion step carried out by the actin/myosin complex, which generates force through ATP hydrolysis. The artery is a vessel carrying blood away from the heart. This term encompasses the physiological and molecular events that lead to contraction of arterial smooth muscle, including excitation-contraction coupling, myosin light chain phosphorylation, and cross-bridge cycling.
Why Is artery smooth muscle contraction Important in Cell Biology?
Artery smooth muscle contraction is essential for maintaining vascular tone and regulating blood flow to tissues. Dysregulation of this process contributes to major cardiovascular diseases, including hypertension, coronary vasospasm, and pulmonary arterial hypertension. Understanding the molecular mechanisms of GO:0014824 helps identify therapeutic targets and explains how drugs like cyclosporine and simvastatin affect arterial contractility. Moreover, the mechanical consequences of arterial smooth muscle contraction, such as increased critical buckling pressure, link cellular events to vessel wall stability and remodeling. Research on this term also informs tissue engineering and the development of gene-edited models to study vascular function.
• Regulates vascular resistance and systemic blood pressure.
• Controls organ perfusion and oxygen delivery.
• Dysfunction leads to hypertension, vasospasm, and ischemic disease.
• Target of immunosuppressants and statins with vascular side effects.
• Involved in rhythmic contractile patterns in cerebral and carotid arteries.
• Modulated by RhoA/ROCK and calcium signaling pathways.
• Mechanical output affects arterial wall buckling and stability.
• Provides a model for studying smooth muscle heterogeneity across vascular beds.
• Key for developing gene-edited cell models of vascular disease.
• Relevant to prostate smooth muscle contraction through shared signaling components.
What Happens During artery smooth muscle contraction?
Excitation and Calcium Influx
In simple terms: The muscle cell gets excited, and calcium enters to start the contraction.
Arterial smooth muscle contraction begins with an increase in intracellular calcium, often through voltage-gated or receptor-operated calcium channels. This calcium binds to calmodulin and activates myosin light chain kinase (MLCK), initiating the contractile cascade. In some arteries, rhythmic contractions can occur spontaneously or in response to agonists like histamine, reflecting oscillatory calcium signaling.
Myosin Light Chain Phosphorylation
In simple terms: A phosphate group is added to myosin, enabling it to interact with actin and generate force.
Activated MLCK phosphorylates the regulatory light chain of myosin, which enables actin-activated myosin ATPase activity and cross-bridge cycling. Protein phosphorylation during contraction-relaxation-contraction cycles of arterial smooth muscle has been demonstrated, highlighting the dynamic regulation of this step. Dephosphorylation by myosin light chain phosphatase promotes relaxation, and the balance between kinase and phosphatase activities determines contractile tone.
Actin-Myosin Cross-Bridge Cycling and Force Generation
In simple terms: Myosin pulls on actin filaments, shortening the muscle cell and narrowing the artery.
Phosphorylated myosin heads bind to actin filaments and undergo ATP-dependent conformational changes that generate force. This chemo-mechanical energy conversion is the core of GO:0014824. The orientation of smooth muscle cells within the arterial wall influences how this force translates into vessel constriction, as shown in human cerebral arteries. The generated force can increase the critical buckling pressure of arteries, affecting wall stability.
Rhythmic and Tonic Contraction Patterns
In simple terms: Some arteries contract in waves, while others maintain steady tension.
Arterial smooth muscle can exhibit rhythmic contractions, as observed in hog carotid artery in response to histamine. Rhythmicity in arterial smooth muscle is a well-recognized phenomenon that depends on ion channel activity and intracellular calcium oscillations. In contrast, tonic contractions are sustained by continuous cross-bridge cycling and are modulated by RhoA/ROCK signaling, which inhibits myosin light chain phosphatase.
Relaxation and Return to Baseline
In simple terms: When calcium drops and myosin is dephosphorylated, the muscle relaxes and the artery widens.
Relaxation occurs when intracellular calcium decreases and myosin light chain phosphatase dephosphorylates myosin, reducing cross-bridge cycling. Endothelium-independent relaxation can be induced by agents like simvastatin, which blocks ROCK and calcium channels in pulmonary artery smooth muscle. The contraction-relaxation cycle is thus a tightly regulated process essential for dynamic blood flow control.
Key Genes Involved in GO:0014824 artery smooth muscle contraction
The following genes and proteins are central to artery smooth muscle contraction (GO:0014824), based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MYH11 | Smooth muscle myosin heavy chain; ATPase motor for force generation | Core contractile protein; mutations linked to aortic disease |
| MYL9 | Myosin regulatory light chain; phosphorylation target of MLCK | Regulates cross-bridge cycling and contraction |
| MYLK | Myosin light chain kinase; phosphorylates MYL9 | Key calcium-dependent regulator of contraction |
| PPP1R12A | Myosin light chain phosphatase regulatory subunit; dephosphorylates MYL9 | Controls relaxation and RhoA/ROCK sensitivity |
| RHOA | Small GTPase; activates ROCK to inhibit MLCP | Modulates calcium sensitization and tonic contraction |
| ROCK1 | Rho-associated kinase; inhibits MLCP and modulates calcium channels | Target of simvastatin in pulmonary artery relaxation |
| ROCK2 | Rho-associated kinase; regulates smooth muscle contractility | Involved in vascular tone and remodeling |
| ACTA2 | Smooth muscle alpha-actin; forms thin filaments | Major actin isoform in arterial smooth muscle |
| CALM1 | Calmodulin; binds calcium to activate MLCK | Calcium-sensing component of contraction |
| CACNA1C | Voltage-gated L-type calcium channel; mediates calcium influx | Regulates excitation-contraction coupling |
| CYTH1 | Cytohesin; activates Rac GTPase | Modulates vascular and prostate smooth muscle contraction |
| RAC1 | Rho-family GTPase; regulates actin dynamics and contraction | Inhibitor studies show effects on arterial contraction |
| PRKCA | Protein kinase C; modulates calcium sensitivity and contraction | Potential regulator of arterial tone |
| PPP1CA | Protein phosphatase 1 catalytic subunit; part of MLCP | Dephosphorylates myosin light chain |
| GNAQ | Gq alpha subunit; mediates agonist-induced calcium release | Couples receptors to contraction |
| PLCB1 | Phospholipase C beta; generates IP3 and DAG | Agonist-induced calcium signaling |
| ITPR1 | IP3 receptor; releases calcium from sarcoplasmic reticulum | Essential for calcium oscillations and rhythmicity |
| NOS3 | Endothelial nitric oxide synthase; produces NO to relax smooth muscle | Modulates arterial tone via endothelium |
How Is artery smooth muscle contraction Regulated?
Artery smooth muscle contraction is regulated by multiple signaling pathways. Calcium-calmodulin activation of MLCK is the primary trigger, while RhoA/ROCK-mediated inhibition of myosin light chain phosphatase promotes calcium sensitization and sustained contraction. Protein kinase C and Rac GTPase pathways further modulate contractile responses, as shown by inhibitor studies in renal and coronary arteries. Cyclosporine can selectively induce renal and coronary artery smooth muscle contraction, suggesting immunophilin-dependent regulation. Simvastatin causes pulmonary artery relaxation by blocking ROCK and calcium channels, demonstrating pharmacological regulation. Rhythmic contractions are regulated by oscillatory calcium release and ion channel activity.
artery smooth muscle contraction and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MYH11 | Aortic aneurysm and dissection | Knock-in of patient mutations in smooth muscle cells |
| ROCK1 | Pulmonary arterial hypertension | Knockout or point mutation to assess relaxation |
| RHOA | Vascular tone dysregulation | Overexpression or knockout in arterial smooth muscle cells |
| CYTH1 | Coronary vasospasm | Knockout in coronary artery smooth muscle cells |
| ACTA2 | Aortic aneurysm and stroke | Point mutation knock-in in induced pluripotent stem cells |
Hypertension and Vasospasm
Increased arterial smooth muscle contraction contributes to hypertension and vasospasm. Cyclosporine-induced renal and coronary artery contraction may underlie its cardiovascular side effects. Simvastatin-induced pulmonary artery relaxation suggests that statins modulate vascular tone, with implications for pulmonary hypertension. Rhythmic contractions in cerebral arteries may play a role in migraine and stroke.
Coronary and Renal Artery Disease
Selective contraction of coronary and renal arteries by cyclosporine highlights the clinical importance of artery-specific smooth muscle responses. Rac GTPase, cytohesin, and kinase inhibitors show shared and distinct patterns of inhibition in renal interlobar and coronary arteries, offering potential therapeutic targets for vasospastic disorders.
Pulmonary Arterial Hypertension
Simvastatin causes pulmonary artery relaxation by blocking smooth muscle ROCK and calcium channels, providing evidence for endothelium-independent mechanisms that could be exploited in pulmonary arterial hypertension. RhoA/ROCK signaling is a key regulator of pulmonary vascular tone.
Aortic Aneurysm and Wall Stability
Smooth muscle cell contraction increases the critical buckling pressure of arteries, and impaired contractility may reduce wall stability and predispose to aneurysm formation. Mutations in contractile proteins like MYH11 and ACTA2 are linked to aortic disease, underscoring the relevance of GO:0014824 to vascular pathology.
From artery smooth muscle contraction-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of MYH11 impair arterial contraction? | MYH11 knockout smooth muscle cell line or mouse model |
| Does a point mutation in ACTA2 alter contractile force? | ACTA2 point-mutation knock-in in vascular smooth muscle cells |
| Can overexpression of ROCK1 increase calcium sensitization? | ROCK1 overexpression in arterial smooth muscle cells |
| Does tagged MYL9 reveal phosphorylation dynamics? | Tagged knock-in of MYL9 for live-cell imaging |
| Does CYTH1 knockout affect coronary artery contraction? | CYTH1 knockout in coronary smooth muscle cells |
| Does simvastatin target ROCK in pulmonary artery? | ROCK1/2 knockout or point mutation in pulmonary artery smooth muscle |
How to Study the artery smooth muscle contraction Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Isometric tension recording | Force generated by arterial rings | Assessing contractile responses to agonists |
| Phospho-protein Western blot | Phosphorylation of myosin light chain | Monitoring contraction-relaxation cycles |
| Calcium imaging | Intracellular calcium concentration | Studying rhythmic contractions and calcium signaling |
| CRISPR knockout | Loss-of-function effects on contraction | Identifying essential genes for arterial contractility |
| Point mutation knock-in | Effect of specific mutations on contractile force | Modeling human vascular disease variants |
| Overexpression | Gain-of-function effects on contraction | Testing if a gene enhances contractility |
| Pharmacological inhibition | Acute modulation of contraction | Screening vasoactive compounds |
| Buckling pressure measurement | Mechanical stability of arteries | Linking contraction to wall mechanics |
Contractility Assays
Isometric tension measurements on arterial rings or strips are used to quantify contraction in response to agonists like histamine or cyclosporine. These assays can assess the effects of gene knockouts or pharmacological inhibitors on force generation.
Phosphorylation Analysis
Western blotting with phospho-specific antibodies against myosin light chain and other contractile proteins reveals the phosphorylation state during contraction-relaxation cycles. This method is critical for understanding the molecular basis of GO:0014824.
Calcium Imaging
Fluorescent calcium indicators (e.g., Fura-2) allow real-time measurement of intracellular calcium oscillations in arterial smooth muscle cells, linking calcium signaling to rhythmic contractions.
Genetic and Pharmacological Perturbation
CRISPR knockout, point mutation, or overexpression of candidate genes (e.g., MYH11, ROCK1, CYTH1) combined with contractility assays can establish causality. Inhibitor studies with Rac, cytohesin, and kinase inhibitors further dissect pathways.
How CRISPR Can Be Used to Study GO:0014824 artery smooth muscle contraction
Knockout
CRISPR knockout of genes such as MYH11, ROCK1, or CYTH1 in arterial smooth muscle cells can reveal their necessity for contraction. For example, knockout of ROCK1 may reduce calcium sensitization and force generation. These models help validate targets identified in pharmacological studies.
Point Mutation
Introducing disease-associated point mutations (e.g., in ACTA2 or MYH11) via CRISPR allows precise modeling of how single amino acid changes affect contractility and vascular stability. Such models are valuable for understanding genotype-phenotype relationships in aortic disease.
Knock-in
Tagged knock-in of contractile proteins (e.g., MYL9 with a fluorescent tag) enables live-cell imaging of protein dynamics during contraction. Knock-in of reporter genes under endogenous promoters can also track smooth muscle differentiation and contractile gene expression.
Overexpression
CRISPR activation or cDNA overexpression of genes like RHOA or ROCK1 can test whether increased signaling enhances arterial contraction. Overexpression models are useful for studying gain-of-function mechanisms in hypertension and vasospasm.
How EDITGENE Supports artery smooth muscle contraction Research
Researchers studying artery smooth muscle contraction-related genes often need to determine whether a candidate gene is causally involved in force generation, calcium sensitization, or vascular tone. EDITGENE provides a comprehensive suite of CRISPR-based services to create precisely engineered cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for artery smooth muscle contraction research.
Frequently Asked Questions About artery smooth muscle contraction
What is GO:0014824 artery smooth muscle contraction?
GO:0014824 is a Gene Ontology biological process term describing force generation within arterial smooth muscle tissue via actin/myosin ATP hydrolysis, leading to changes in muscle geometry.
What genes are involved in artery smooth muscle contraction?
Key genes include MYH11, MYL9, MYLK, RHOA, ROCK1, ROCK2, ACTA2, and CACNA1C, among others.
How is artery smooth muscle contraction regulated?
It is regulated by calcium-calmodulin activation of MLCK, RhoA/ROCK-mediated calcium sensitization, and phosphorylation-dephosphorylation cycles of myosin light chain.
What diseases are associated with abnormal artery smooth muscle contraction?
Hypertension, coronary vasospasm, pulmonary arterial hypertension, and aortic aneurysm are linked to dysregulated arterial contractility.
What methods are used to study artery smooth muscle contraction?
Isometric tension recording, phosphorylation analysis, calcium imaging, and CRISPR-based genetic perturbation are common methods.
Can CRISPR be used to study artery smooth muscle contraction?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models allow precise dissection of gene function in arterial contractility.
What is the role of myosin light chain phosphorylation in arterial contraction?
Phosphorylation of myosin light chain by MLCK enables actin-myosin cross-bridge cycling and force generation, while dephosphorylation promotes relaxation.
How does RhoA/ROCK signaling affect arterial smooth muscle?
RhoA/ROCK inhibits myosin light chain phosphatase, increasing calcium sensitivity and sustaining contraction.
What is the significance of rhythmic contractions in arteries?
Rhythmic contractions, observed in cerebral and carotid arteries, contribute to vascular tone and may be involved in migraine and stroke.
How does simvastatin affect pulmonary artery smooth muscle?
Simvastatin causes pulmonary artery relaxation by blocking ROCK and calcium channels through an endothelium-independent mechanism.
Conclusion
GO:0014824 artery smooth muscle contraction is a central biological process that governs vascular tone and blood flow. Its molecular basis involves calcium signaling, myosin light chain phosphorylation, and actin-myosin cross-bridge cycling, with critical roles for RhoA/ROCK and other regulatory pathways. Dysregulation of this process contributes to hypertension, vasospasm, and aneurysm, making it a key area for therapeutic intervention. CRISPR-based models and pharmacological tools continue to advance our understanding of the genes and mechanisms underlying arterial contractility.
References
- 1. Haddock RE et al.. 2005. Rhythmicity in arterial smooth muscle.. J Physiol 566(Pt 3):645-56 PMID: 15905215
- 2. Liu G et al.. 2025. Vasoactivity of Rac GTPase, Cytohesin and Kinase Inhibitors in Renal Interlobar and Coronary Arteries Reveals Shared and Distinct Patterns of Inhibitory Effects in Vascular and Prostate Smooth Muscle Contraction.. Pharmacol Res Perspect 13(6):e70190 PMID: 41252219
- 3. Epstein A et al.. 1998. Cyclosporine, but not FK506, selectively induces renal and coronary artery smooth muscle contraction.. Surgery 123(4):456-60 PMID: 9551073
- 4. Walmsley JG et al.. 1983. Interrelationships among wall structure, smooth muscle orientation, and contraction in human major cerebral arteries.. Stroke 14(5):781-90 PMID: 6197786
- 5. Bárány M et al.. 1992. Protein phosphorylation during the contraction-relaxation-contraction cycle of arterial smooth muscle.. Arch Biochem Biophys 294(2):571-8 PMID: 1567213
- 6. Absi M et al.. 2019. Simvastatin causes pulmonary artery relaxation by blocking smooth muscle ROCK and calcium channels: Evidence for an endothelium-independent mechanism.. PLoS One 14(8):e0220473 PMID: 31369604
- 7. Stein PG et al.. 1984. Histamine-induced rhythmic contraction of hog carotid artery smooth muscle.. Circ Res 55(4):480-5 PMID: 6478552
- 8. Hayman DM et al.. 2013. Smooth muscle cell contraction increases the critical buckling pressure of arteries.. J Biomech 46(4):841-4 PMID: 23261241
